Clinical trial
HR POSITIVE, HER 2 NEGATIVE ADVANCED BREAST CANCER- TREATMENT PATTERNS IN POLAND - HABER STUDY
NCT05478590 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- HR POSITIVE, HER 2 NEGATIVE ADVANCED BREAST CANCER- TREATMENT PATTERNS IN POLAND - HABER STUDY
- Lead sponsor
- Pfizer
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 22, 2021
- Completion date
- September 30, 2022
- Enrollment
- 440 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.